{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:43:17Z","timestamp":1787726597690,"version":"build-2784847793"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Helicobacter pylori infection, a global health concern, is treated with various antibiotic regimens, but rising resistance causes variable outcomes. This meta-analysis evaluated the efficacy and safety of different eradication regimens. Methods PubMed, Embase, and Web of Science were searched from inception to October 2025. Randomized and observational studies reporting eradication rates or adverse events were included. Pooled estimates were calculated using random-effects models with subgroup analyses and meta-regression. Results Fifty-seven studies (19,941 participants, 127 arms) were included. The pooled eradication rate was 83.0% (95% CI: 81.4%\u201384.5%; I\u00b2=87.3%). Egger's and Begg's tests indicated publication bias (both\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.001); trim-and-fill adjusted rate was 78.1%. Subgroup analyses showed sequential (84.3%), quadruple (83.3%), and dual therapy (83.8%) achieved slightly higher rates than triple therapy (79.2%). PCAB-based regimens outperformed PPI-based (85.3% vs. 81.6%). Ten-day regimens yielded higher rates (85.9%) than 7-day (79.8%) or 14-day (82.7%). Regimens with three antibiotics (86.9%) or nitroimidazoles (84.8%) showed improved efficacy. Meta-regression identified publication year, continent, study design, and acid suppressant as heterogeneity sources (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt;0.01). For safety (54 studies, 119 arms, 5,202 events), pooled adverse event incidence was 26.1% (95% CI: 21.0%\u201331.9%; I\u00b2=95.3%). Sequential therapy had the highest incidence (54.1%), dual therapy the lowest (15.8%). Regimens with three antibiotics (52.6%), macrolides (29.0%), or nitroimidazoles (37.1%) were associated with more adverse events. Conclusions Eradication regimens vary in efficacy and safety; treatment selection should balance these factors. Findings require confirmation due to high heterogeneity and between-study comparisons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      CRD420251207695,\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251207695<\/jats:uri>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1780052","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:24:37Z","timestamp":1775535877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of antibiotic regimens for Helicobacter pylori eradication: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yinhua","family":"Liao","sequence":"first","affiliation":[{"name":"Bengbu Medical University","place":["Bengbu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liu","sequence":"additional","affiliation":[{"name":"Anhui Provincial Cancer Hospital","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Department, Shaoxing University","place":["Shaoxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2438735","DOI":"10.1080\/21505594.2024.2438735","article-title":"Pathogenicity and virulence of Helicobacter pylori: a paradigm of chronic infection","volume":"16","author":"Clyne","year":"2025","journal-title":"Virulence"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1365-2036.1996.22164006.x","article-title":"The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration","volume":"10","author":"Mobley","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1053\/gast.1996.v110.pm8608904","article-title":"Helicobacter pylori and gastric acid: biological and therapeutic implications","volume":"110","author":"McGowan","year":"1996","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/s2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.12998\/wjcc.v10.i19.6349","article-title":"Current guidelines for Helicobacter pylori treatment in East Asia 2022: differences among China, Japan, and South Korea","volume":"10","author":"Cho","year":"2022","journal-title":"World J Clin Cases"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e13040","DOI":"10.1111\/hel.13040","article-title":"Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"29","author":"Zhou","year":"2024","journal-title":"Helicobacter"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1155\/2007\/419784","article-title":"A meta-analysis of the success rate of Helicobacter pylori therapy in Canada","volume":"21","author":"Rodgers","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2147\/IJGM.S452348","article-title":"Recurrence rate and influencing factors of Helicobacter pylori infection after successful eradication in southern coastal China","volume":"17","author":"Zhang","year":"2024","journal-title":"Int J Gen Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/MEG.0000000000002733","article-title":"High antibiotic resistance rates in Helicobacter pylori strains in Turkey over 20 years: implications for gastric disease treatment","volume":"36","author":"Sar\u0131kaya","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.3390\/life12122038","article-title":"Helicobacter pylori: a review of current treatment options in clinical practice","volume":"12","author":"Roberts","year":"2022","journal-title":"Life"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/MCG.0b013e31826015b0","article-title":"Nonbismuth quadruple \"concomitant\" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial","volume":"47","author":"Georgopoulos","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.47391\/JPMA.SRPH-28","article-title":"Retrospective analysis of the clinical efficacy of minocycline regimen in the radical treatment of Helicobacter pylori and its adverse reactions","volume":"75","author":"Zhao","year":"2025","journal-title":"J Pak Med Assoc"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e13148","DOI":"10.1111\/hel.13148","article-title":"Efficacy and safety of vonoprazan in dual\/triple\/quadruple regimens both in first-line and rescue therapy for Helicobacter pylori eradication: a systematic review with meta-analysis","volume":"29","author":"Benito","year":"2024","journal-title":"Helicobacter"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e70101","DOI":"10.1111\/hel.70101","article-title":"Antibiotic combinations in bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and network meta-analysis","volume":"30","author":"Duan","year":"2025","journal-title":"Helicobacter"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"12954","DOI":"10.3748\/wjg.v21.i45.12954","article-title":"Hybrid therapy for Helicobacter pylori infection: a systemic review and meta-analysis","volume":"21","author":"Hsu","year":"2015","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/apt.13495","article-title":"Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection","volume":"43","author":"Liou","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/ajg.2009.508","article-title":"Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of efficacy and tolerability","volume":"105","author":"Luther","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1523-5378.2009.00671.x","article-title":"Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing \"concomitant therapy\" versus triple therapy for Helicobacter pylori eradication","volume":"14","author":"Essa","year":"2009","journal-title":"Helicobacter"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"9781212","DOI":"10.1155\/2019\/9781212","article-title":"Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized clinical trials","volume":"2019","author":"Lyu","year":"2019","journal-title":"Biomed Res Int"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"420","DOI":"10.5152\/tjg.2019.18693","article-title":"Standard triple therapy in Helicobacter pylori eradication in Turkey: systematic evaluation and meta-analysis of 10-year studies","volume":"30","author":"Sezgin","year":"2019","journal-title":"Turk J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref24","volume-title":"Validity and Inter-Rater Reliability Testing of Quality Assessment Instruments","author":"Hartling","year":"2012"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4132\/jptm.2017.04.03","article-title":"Rare gastric lesions associated with Helicobacter pylori infection: a histopathological review","volume":"51","author":"Joo","year":"2017","journal-title":"J Pathol Transl Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2025.08.015","article-title":"The disease burden of Helicobacter pylori beyond gastric cancer: quantifying the forgotten potential benefits of mass eradication","volume":"170","author":"M\u00fclder","year":"2026","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nrc2857","article-title":"Helicobacter pylori: gastric cancer and beyond","volume":"10","author":"Polk","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-024-01654-2","article-title":"Helicobacter pylori and gastric cancer: mechanisms and new perspectives","volume":"18","author":"Duan","year":"2025","journal-title":"J Hematol Oncol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11894-016-0509-x","article-title":"Eradication of Helicobacter pylori infection","volume":"18","author":"Marcus","year":"2016","journal-title":"Curr Gastroenterol Rep"},{"key":"ref31","first-page":"236","article-title":"Diagnosis and treatment of peptic ulcer disease and H. pylori infection","volume":"91","author":"Fashner","year":"2015","journal-title":"Am Fam Physician"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gut.2007.125658","article-title":"The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis","volume":"56","author":"Zullo","year":"2007","journal-title":"Gut"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/jac\/43.5.659","article-title":"Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts","volume":"43","author":"Stratton","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jcph.195","article-title":"Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy","volume":"54","author":"Furuta","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","article-title":"Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis","volume":"9","author":"Hong","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/jgh.70227","article-title":"Antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a call for coordinated regional strategies","volume":"41","author":"Otani","year":"2026","journal-title":"J Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.3748\/wjg.v20.i18.5283","article-title":"Treatment of Helicobacter pylori infection: current status and future concepts","volume":"20","author":"Yang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and Meta-analysis in World Health Organization regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.12998\/wjcc.v4.i1.5","article-title":"Treatment of Helicobacter pylori infection: current and future insights","volume":"4","author":"Safavi","year":"2016","journal-title":"World J Clin Cases"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cgh.2009.09.030","article-title":"Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection","volume":"8","author":"Wu","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3390\/antibiotics9080436","article-title":"Best Helicobacter pylori eradication strategy in the era of antibiotic resistance","volume":"9","author":"Kim","year":"2020","journal-title":"Antibiotics"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3390\/jcm9020543","article-title":"Clarithromycin versus metronidazole in first-line Helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: meta-analysis","volume":"9","author":"Murata","year":"2020","journal-title":"J Clin Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1590\/s0004-28032003000100012","article-title":"The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy","volume":"40","author":"Eisig","year":"2003","journal-title":"Arq Gastroenterol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e3879","DOI":"10.1097\/MD.0000000000003879","article-title":"A 2-week nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: a single center experience","volume":"95","author":"Abd-Elsalam","year":"2016","journal-title":"Medicine"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5009\/gnl.2012.6.4.434","article-title":"Comparison of the eradication rate between 1- and 2-week bismuth-containing quadruple rescue therapies for Helicobacter pylori eradication","volume":"6","author":"Yoon","year":"2012","journal-title":"Gut Liver"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"223","DOI":"10.34172\/mejdd.2021.229","article-title":"Comparison between hybrid, reverse hybrid, and non-bismuth levofloxacin quadruple regimens for Helicobacter pylori infection in Egypt: a randomized trial","volume":"13","author":"Fathy El Sayed","year":"2021","journal-title":"Middle East J Dig Dis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"109001","DOI":"10.3748\/wjg.v31.i28.109001","article-title":"Efficacy and safety of triple therapy with vonoprazan for Helicobacter pylori eradication: a multicenter, prospective, randomized controlled trial","volume":"31","author":"Han","year":"2025","journal-title":"World J Gastroenterol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1097\/CM9.0000000000002289","article-title":"Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial","volume":"135","author":"Bi","year":"2022","journal-title":"Chin Med J"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1049908","DOI":"10.3389\/fimmu.2022.1049908","article-title":"Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: a prospective, open-labeled, randomized non-inferiority clinical study","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.cgh.2024.01.022","article-title":"Efficacy and safety of vonoprazan-amoxicillin dual regimen with varying dose and duration for Helicobacter pylori eradication: a multicenter, prospective, randomized study","volume":"22","author":"Peng","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.14309\/ctg.0000000000000699","article-title":"Comparison of the efficacy between the dual therapy of Tegoprazan and the quadruple therapy of Tegoprazan: a randomized controlled multicenter study","volume":"15","author":"Liu","year":"2024","journal-title":"Clin Transl Gastroenterol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"107320","DOI":"10.1016\/j.ijantimicag.2024.107320","article-title":"The efficacy of keverprazan-based quadruple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind, multicentre trial","volume":"64","author":"Tan","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/s12879-021-06356-5","article-title":"Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for Helicobacter pylori infection: a prospective single-center randomized controlled trial","volume":"21","author":"Alhalabi","year":"2021","journal-title":"BMC Infect Dis"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"965","DOI":"10.12669\/pjms.38.4.5436","article-title":"Comparison of Vonoprazan and amoxicillin dual therapy with standard triple therapy with proton pump inhibitor for Helicobacter pylori eradication: a randomized control trial","volume":"38","author":"Zuberi","year":"2022","journal-title":"Pak J Med Sci"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4318\/tjg.2013.0509","article-title":"A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients","volume":"24","author":"Av\u015far","year":"2013","journal-title":"Turk J Gastroenterol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/gut.2006.102269","article-title":"Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER study","volume":"56","author":"Zagari","year":"2007","journal-title":"Gut"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1272744","DOI":"10.3389\/fphar.2023.1272744","article-title":"Efficacy and safety of high-dose ilaprazole-amoxicillin dual therapy for Helicobacter pylori eradication: a prospective, single-center, randomized trial","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1629567","DOI":"10.3389\/fmed.2025.1629567","article-title":"Tegoprazan dual and quadruple therapy for Helicobacter pylori eradication: a prospective, randomized controlled trial in Beijing, China","volume":"12","author":"Cheng","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"605","DOI":"10.5009\/gnl13303","article-title":"The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea","volume":"8","author":"Chung","year":"2014","journal-title":"Gut Liver"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"927","DOI":"10.22034\/APJCP.2017.18.4.927","article-title":"Outcomes of a randomized controlled trial comparing modified high dose omeprazole and amoxicillin triple therapy with standard triple therapy for Helicobacter pylori eradication","volume":"18","author":"Chunlertlith","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/s12876-025-04226-x","article-title":"Efficacy of a 7-day vonoprazan, sitafloxacin, and amoxicillin triple therapy as a fourth-line salvage regimen for refractory Helicobacter pylori infection","volume":"25","author":"Geeratragool","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1543352","DOI":"10.3389\/fphar.2025.1543352","article-title":"Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication of Helicobacter pylori infection with vonoprazan amoxicillin: a prospective, multicenter, randomized controlled trial","volume":"16","author":"Dong","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1590\/s0004-28032003000100012","article-title":"The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy","volume":"40","author":"Eisig","year":"2003","journal-title":"Arq Gastroenterol"},{"key":"ref65","first-page":"887","article-title":"Efficacy of short-duration Furazolidone in two different quadruple regimens for H. pylori eradication","volume":"27","author":"Tirgar Fakheri","year":"2011","journal-title":"Pakistan J Medical Sciences Online"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e12918","DOI":"10.1111\/hel.12918","article-title":"Eradication rate and safety of a \"simplified rescue therapy\": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: a real-world, retrospective clinical study in China","volume":"27","author":"Gao","year":"2022","journal-title":"Helicobacter"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e13070","DOI":"10.1002\/jgh3.13070","article-title":"Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: real-world evidence","volume":"8","author":"He","year":"2024","journal-title":"JGH Open"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1143969","DOI":"10.3389\/fphar.2023.1143969","article-title":"The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1159\/000484930","article-title":"Comparison of Helicobacter pylori eradication rates of 2-week levofloxacin-containing triple therapy, levofloxacin-containing bismuth quadruple therapy, and standard bismuth quadruple therapy as a first-line regimen","volume":"26","author":"Kahramano\u011flu Aksoy","year":"2017","journal-title":"Med Princ Pract"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1756284819870960","DOI":"10.1177\/1756284819870960","article-title":"Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections","volume":"12","author":"Kuo","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.rgmx.2018.04.005","article-title":"Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: results from an open-label, randomized, noninferiority phase iiib trial","volume":"84","author":"Ladr\u00f3n-de-Guevara","year":"2019","journal-title":"Rev Gastroenterol Mex"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.2147\/IDR.S417711","article-title":"A modified 14-day dual therapy with Vonoprazan and amoxicillin amplified the advantages over conventional therapies for eradication of Helicobacter pylori: a non-inferiority clinical trial","volume":"16","author":"Li","year":"2023","journal-title":"Infect Drug Resist"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"17562848251366156","DOI":"10.1177\/17562848251366156","article-title":"Vonoprazan-minocycline dual therapy as a first-line treatment of Helicobacter pylori infection compared with empirical bismuth-containing quadruple therapy","volume":"18","author":"Li","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"e70233","DOI":"10.1002\/jgh3.70233","article-title":"Efficacy and safety of 10-day minocycline twice daily in bismuth-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: a prospective single-arm study","volume":"9","author":"Li","year":"2025","journal-title":"JGH Open"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1111\/jgh.16679","article-title":"Comparison of vonoprazan bismuth-containing triple therapy with quadruple therapy in Helicobacter pylori-infected treatment-naive patients: a prospective multicenter randomized controlled trial","volume":"39","author":"Liang","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.cgh.2013.01.008","article-title":"Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study","volume":"11","author":"Liang","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"100863","DOI":"10.3748\/wjg.v31.i13.100863","article-title":"Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: proton pump inhibitor and potassium-competitive acid blocker, which's better?","volume":"31","author":"Yang","year":"2025","journal-title":"World J Gastroenterol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"16318","DOI":"10.1038\/s41598-025-01117-9","article-title":"Randomized multicenter trial comparing minocycline and ornidazole with classical quadruple therapy in Helicobacter pylori treatment","volume":"15","author":"Lin","year":"2025","journal-title":"Sci Rep"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"987","DOI":"10.21037\/atm-22-4133","article-title":"The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study","volume":"10","author":"Lin","year":"2022","journal-title":"Ann Transl Med"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3748\/wjg.v21.i2.661","article-title":"Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication","volume":"21","author":"Mansour-Ghanaei","year":"2015","journal-title":"World J Gastroenterol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"e11837","DOI":"10.7759\/cureus.11837","article-title":"Non-bismuth quadruple therapy, sequential therapy or high-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a prospective randomized study","volume":"12","author":"Zeriouh","year":"2020","journal-title":"Cureus"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"19","DOI":"10.22037\/ghfbb.v0i0.1191","article-title":"Levofloxacin based vs clarithromycin based sequential therapy in Helicobacter pylori eradication; a randomized clinical trial","volume":"11","author":"Moradniani","year":"2018","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"771876","DOI":"10.3389\/fphar.2022.771876","article-title":"Comparison of the dual therapy of Ilaprazole-amoxicillin and the bismuth quadruple therapy of Ilaprazole-amoxicillin-Furazolidone-bismuth Glycyrrhizinate for eradication of Helicobacter pylori","volume":"13","author":"Niu","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.3390\/jpm12111918","article-title":"Comparative efficacy of 14-day Tegoprazan-based triple vs. 10-day Tegoprazan-based concomitant therapy for Helicobacter pylori eradication","volume":"12","author":"Park","year":"2022","journal-title":"J Pers Med"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.3748\/wjg.v11.i16.2477","article-title":"Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients","volume":"11","author":"Sun","year":"2005","journal-title":"World J Gastroenterol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.3748\/wjg.v13.i21.2967","article-title":"Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile","volume":"13","author":"Riquelme","year":"2007","journal-title":"World J Gastroenterol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/07853890.2022.2031269","article-title":"The prospective multiple-Centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in Sichuan areas","volume":"54","author":"Shen","year":"2022","journal-title":"Ann Med"},{"key":"ref88","author":"Shiekh","year":"2022"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"e5859","DOI":"10.1097\/MD.0000000000005859","article-title":"Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: a 1-week, open-label, randomized trial","volume":"96","author":"Su","year":"2017","journal-title":"Medicine Baltimore"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/CM9.0000000000002629","article-title":"Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: a randomized controlled trial","volume":"136","author":"Suo","year":"2023","journal-title":"Chin Med J"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jmii.2024.02.009","article-title":"The multicenter real-world report of the efficacies of 14-day esomeprazole-based and rabeprazole-based high-dose dual therapy in first-line Helicobacter pylori eradication in Taiwan","volume":"57","author":"Tai","year":"2024","journal-title":"J Microbiol Immunol Infect"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"e0175625","DOI":"10.1371\/journal.pone.0175625","article-title":"Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: a prospective, multicenter, randomized clinical trial","volume":"12","author":"Tan","year":"2017","journal-title":"PLoS One"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1097\/MCG.0000000000002100","article-title":"Clinical impact of high-dose esomeprazole-amoxicillin dual therapy as rescue treatment for Helicobacter pylori infection: a prospective, multicenter, randomized trial","volume":"59","author":"Wang","year":"2025","journal-title":"J Clin Gastroenterol"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"17562848231190976","DOI":"10.1177\/17562848231190976","article-title":"Efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial","volume":"16","author":"Wang","year":"2023","journal-title":"Ther Adv Gastroenterol"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"1096103","DOI":"10.3389\/fphar.2023.1096103","article-title":"14-day pantoprazole- and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: a prospective, randomized controlled trial","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/ueg2.70070","article-title":"Efficacy and safety of Vonoprazan and high-dose amoxicillin dual therapy for rescue treatment of Helicobacter pylori infection: a multicenter randomized controlled trial","volume":"13","author":"Zhang","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"9251879","DOI":"10.1155\/2019\/9251879","article-title":"Application of minocycline-containing bismuth quadruple therapies as first-line regimens in the treatment of Helicobacter pylori","volume":"2019","author":"Zhang","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.3748\/wjg.v30.i39.4295","article-title":"Efficacy and safety of low-dose tetracycline, amoxicillin quadruple therapy in Helicobacter pylori infection: a retrospective single center study","volume":"30","author":"Zhao","year":"2024","journal-title":"World J Gastroenterol"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"17562848241309870","DOI":"10.1177\/17562848241309870","article-title":"Ten-day vonoprazan-amoxicillin dual therapy versus 14-day esomeprazole-amoxicillin dual therapy for first-line Helicobacter pylori eradication: a prospective multicenter randomized controlled trial","volume":"17","author":"Zhou","year":"2024","journal-title":"Ther Adv Gastroenterol"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"e40170","DOI":"10.1097\/MD.0000000000040170","article-title":"Efficacy and safety of vonoprazan-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: a large-scale, real-world study","volume":"103","author":"Zhou","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"goae036","DOI":"10.1093\/gastro\/goae036","article-title":"The efficacy and safety of vonoprazan in quadruple therapy for Helicobacter pylori eradication: a comparative study","volume":"12","author":"Zhuang","year":"2024","journal-title":"Gastroenterol Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1780052\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:24:40Z","timestamp":1775535880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1780052\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":101,"alternative-id":["10.3389\/fmed.2026.1780052"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1780052","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"article-number":"1780052"}}